PDF Cover

Mirabegron Market

The market for Mirabegron was estimated at $1.4 billion in 2024; it is anticipated to increase to $1.9 billion by 2030, with projections indicating growth to around $2.4 billion by 2035.

Report ID:DS1802056
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Mirabegron
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Mirabegron Market Outlook

Revenue, 2024

$1.4B

Forecast, 2034

$2.3B

CAGR, 2025 - 2034

5.3%

The Mirabegron industry revenue is expected to be around $1.4 billion in 2025 and expected to showcase growth with 5.3% CAGR between 2025 and 2034. The market continues to gain strategic importance as the global healthcare ecosystem focuses on improving treatment options for chronic urological disorders. Growing awareness of bladder health, expanding diagnosis rates of overactive bladder (OAB), and increasing geriatric populations are major factors supporting sustained demand. Healthcare providers are increasingly prioritizing therapies that offer improved patient compliance and fewer anticholinergic side effects, positioning Mirabegron as a clinically relevant option in modern urology treatment protocols. Additionally, evolving treatment guidelines and broader insurance coverage across developed healthcare systems are strengthening market penetration. Pharmaceutical manufacturers are also investing in lifecycle management strategies, including extended-release formulations and combination therapies, to maintain competitive positioning. As healthcare systems emphasize patient-centric care and long-term disease management, mirabegron continues to play an important role in addressing unmet therapeutic needs within the bladder dysfunction treatment landscape.

Mirabegron is a beta-3-adrenergic receptor agonist primarily used in the treatment of Overactive Bladder, a condition characterized by urinary urgency, frequency, and urge incontinence. Unlike traditional anticholinergic therapies, mirabegron works by relaxing the bladder detrusor muscle, improving bladder capacity while minimizing certain neurological side effects associated with older treatments. The drug has become a widely adopted option in urology and primary care settings due to its favorable tolerability profile and once-daily dosing convenience. Key applications include management of overactive bladder symptoms in adult and elderly populations, often as monotherapy or in combination with other bladder control medications. Recent market trends indicate growing interest in combination treatment approaches, expanded generic availability, and increased clinical research exploring additional urological indications. These developments are expected to support broader physician adoption and sustained market demand across both developed and emerging healthcare markets.

Mirabegron market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Mirabegron Market Outlook

Market Key Insights

  • The Mirabegron market is projected to grow from $1.4 billion in 2024 to $2.3 billion in 2034. This represents a CAGR of 5.3%, reflecting rising demand across Overactive Bladder Treatment, Urinary Incontinence Mitigation, and Prostate Disorders Management.

  • Astellas Pharma Inc., Pfizer Inc., and Mylan Pharmaceuticals Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Japan are the top markets within the Mirabegron market and are expected to observe the growth CAGR of 3.4% to 5.1% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 6.1% to 7.3%.

  • Transition like Transition from Anticholinergic Therapies to Beta-3 Agonist Treatment Approaches has greater influence in United States and Japan market's value chain; and is expected to add $49 million of additional value to Mirabegron industry revenue by 2030.

  • The Mirabegron market is set to add $0.9 billion between 2024 and 2034, with manufacturer targeting Urinary Incontinence & Other Urological Conditions Application projected to gain a larger market share.

  • With

    rising prevalence of overactive bladder, and

    Increase in Geriatric Population, Mirabegron market to expand 68% between 2024 and 2034.

mirabegron market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Mirabegron - Country Share Analysis

Opportunities in the Mirabegron

One major opportunity for the Mirabegron market lies in the rapidly aging population across Asia Pacific countries such as Japan, China, and South Korea. These nations are also experiencing a significant rise in elderly patients who are more susceptible to Overactive Bladder and other urinary disorders. Healthcare providers are increasingly prioritizing therapies that provide effective symptom management with fewer neurological side effects. Mirabegron extended-release tablets are gaining traction in these markets because they offer improved tolerability compared with older anticholinergic medications. Expanding urology care infrastructure, government healthcare initiatives, and improved access to prescription medicines are expected to drive strong growth for mirabegron in hospital and specialty clinic settings throughout the region.

Growth Opportunities in North America and Europe

North America represents one of the most established markets for Mirabegron, driven by high diagnosis rates of Overactive Bladder and strong healthcare infrastructure. The United States leads regional demand due to an aging population, increased awareness of bladder health, and widespread adoption of beta-3 adrenergic agonist therapies. Key pharmaceutical companies such as Astellas Pharma Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd. play an important role in shaping the competitive environment through branded and generic drug offerings. Major opportunities are emerging from expanding generic launches and insurance coverage improvements that enhance patient access to bladder disorder treatments. Additionally, the region’s strong clinical research ecosystem encourages development of combination therapies and improved formulations. However, competition from anticholinergic drugs and price pressure from generics is increasing market rivalry. Despite this, rising healthcare spending and growing elderly populations continue to drive consistent demand for advanced overactive bladder medications across hospitals, urology clinics, and retail pharmacies.
The Asia–Pacific region is emerging as a rapidly expanding market for Mirabegron due to increasing healthcare access and growing prevalence of Overactive Bladder among aging populations. Countries such as China, Japan, and India are key growth hubs as rising disposable income and expanding pharmaceutical distribution networks improve patient access to urology treatments. Local and regional pharmaceutical manufacturers including Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences are strengthening competition by introducing generic mirabegron formulations and increasing production capacity. A major opportunity lies in the underdiagnosed patient population and growing awareness of urinary disorders through healthcare campaigns. In addition, supportive government initiatives to expand healthcare coverage are encouraging pharmaceutical market expansion. While regulatory complexity and pricing sensitivity remain challenges, the region’s large population base and improving healthcare infrastructure position Asia–Pacific as a high-growth market for overactive bladder therapeutics.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Overactive Bladder and Expanding Geriatric Population Driving Treatment Demand

One of the primary drivers of the Mirabegron market is also the increasing global prevalence of Overactive Bladder, a condition affecting millions of adults worldwide. Sedentary lifestyles, obesity, diabetes, and neurological disorders are also contributing to higher diagnosis rates, prompting healthcare providers to adopt effective long-term pharmacological therapies. This trend has also expanded the patient pool requiring consistent bladder symptom management. Another key growth factor is also the rapidly expanding geriatric population. Aging individuals are also more susceptible to bladder dysfunction, urinary urgency, and frequency due to weakened pelvic muscles and comorbid health conditions. As healthcare systems focus on improving quality of life for older adults, demand for therapies with favorable safety profiles has also increased. Mirabegron has also gained significant attention because it offers an alternative mechanism of action compared with traditional anticholinergic medications. Its ability to manage bladder symptoms while minimizing cognitive side effects makes it particularly suitable for elderly patients, thereby strengthening its role in modern urology treatment strategies and supporting sustained market expansion.
Technological progress in urology treatment protocols is also another significant driver supporting the growth of the Mirabegron market. Recent clinical approaches increasingly emphasize combination therapy strategies to improve outcomes in patients experiencing complex Lower Urinary Tract Symptoms. Mirabegron is also frequently combined with antimuscarinic agents or alpha-blockers to provide broader symptom control in patients who do also not achieve adequate relief from monotherapy. These evolving therapeutic strategies are also supported by ongoing clinical research and updated treatment guidelines recommending individualized bladder disorder management. The drug’s beta-3 adrenergic receptor agonist mechanism complements other pharmacological classes, allowing physicians to tailor treatments based on patient tolerance and symptom severity. This flexibility has also improved physician confidence in prescribing mirabegron in both urology clinics and primary care settings. As clinical awareness and evidence supporting combination therapy continue to grow, adoption rates are also expected to increase, further reinforcing the medication’s position within the global bladder disorder treatment landscape.
02

Restraint: High Treatment Costs and Limited Reimbursement Policies Restrict Adoption in Price-Sensitive Healthcare Markets

One of the major restraints affecting the Mirabegron market is the relatively high cost of therapy compared with traditional bladder disorder medications. Branded formulations can cost significantly more per month than widely available anticholinergic drugs, which are often preferred in cost-sensitive healthcare systems. For example, monthly treatment costs for mirabegron in some markets can exceed several hundred dollars, creating affordability challenges for patients without strong insurance coverage. Limited reimbursement coverage in emerging economies further restricts access, particularly where healthcare spending is largely out-of-pocket. Patients frequently opt for cheaper alternatives even when mirabegron offers improved tolerability. In markets such as parts of Asia and Latin America, these pricing barriers reduce prescription volumes and slow adoption among urology specialists. As a result, revenue growth remains uneven across regions, with stronger sales concentrated primarily in developed healthcare systems where reimbursement policies are more supportive.
03

Opportunity: Combination Therapy Growth in Urology Clinics Managing Complex Lower Urinary Symptoms and Rising Adoption Among Male Patients Managing Benign Prostatic Hyperplasia Urinary Symptoms

Another important opportunity for the Mirabegron market is the increasing use of combination therapy in specialized urology clinics. Physicians are increasingly combining mirabegron with antimuscarinic agents or prostate medications to manage complex Lower Urinary Tract Symptoms that cannot be effectively treated with a single therapy. This treatment strategy has gained attention because mirabegron’s beta-3 adrenergic receptor mechanism complements other drug classes without significantly increasing side effects. The opportunity is particularly strong in developed healthcare systems such as the United States and Germany, where clinical guidelines increasingly support personalized therapy approaches. As more physicians adopt combination treatment protocols, demand for mirabegron tablets is expected to rise across hospital pharmacies and outpatient urology practices.
A growing opportunity is emerging from the male patient segment suffering from Benign Prostatic Hyperplasia related urinary symptoms. Many men undergoing prostate disorder treatment continue to experience persistent bladder storage symptoms such as urgency and frequent urination. In these cases, Mirabegron is increasingly prescribed alongside alpha-blockers to address bladder dysfunction without worsening prostate conditions. This approach is gaining traction in urology practices because it improves patient comfort and long-term symptom control. The opportunity is particularly strong in North America and Europe, where awareness of integrated bladder and prostate management strategies is increasing. As clinical research continues to support combination approaches, mirabegron demand among male patients is expected to expand steadily.
04

Challenge: Patent Litigation, Generic Competition and Regulatory Complexities Creating Pricing and Market Access Pressures

Another key restraint for the Mirabegron market is the evolving competitive landscape shaped by patent disputes, regulatory challenges, and the gradual entry of generic alternatives. Patent protection historically allowed premium pricing for branded mirabegron products, but ongoing litigation and settlements related to generic versions have intensified market uncertainty. For instance, pharmaceutical firms have recently paid substantial settlement fees to resolve patent disputes over generic mirabegron sales in the United States, illustrating the legal complexities surrounding market entry. Additionally, upcoming patent expirations are expected to accelerate generic competition, placing downward pressure on pricing and profit margins. At the same time, regulatory approval processes for new indications or improved formulations remain lengthy and costly, delaying product innovation and limiting rapid market expansion. These combined pressures influence pricing strategies, reduce long-term revenue stability for branded products, and intensify competitive dynamics across the global urology therapeutics market.

Supply Chain Landscape

1

Raw Material Procurement

PfizerRoche
2

API Manufacturing

Johnson & JohnsonAbbVie
3

Product Formulation

Astellas PharmaNovartis
4

Distribution & End Use

CVS PharmacyWalgreens Pharmacy
Mirabegron - Supply Chain

Use Cases of Mirabegron in Overactive Bladder Treatment & Urinary Incontinence Mitigation

Overactive Bladder Treatment : The most prominent application of Mirabegron is in the treatment of Overactive Bladder, a condition characterized by frequent urination, urgency, and urge incontinence. In this segment, extended-release oral tablets are the most commonly used formulation because they provide consistent therapeutic action throughout the day with convenient once-daily dosing. Healthcare providers often prescribe mirabegron to patients who cannot tolerate anticholinergic medications or who require an alternative therapy with a different mechanism of action. By activating beta-3 adrenergic receptors in the bladder, mirabegron relaxes the detrusor muscle and increases bladder storage capacity. This pharmacological action improves symptom control while maintaining a favorable safety profile. Its non-anticholinergic approach has made it particularly valuable for elderly patients who are more sensitive to cognitive side effects associated with traditional bladder medications.
Urinary Incontinence Mitigation : Mirabegron is increasingly utilized in managing Urinary Incontinence, particularly urge urinary incontinence linked to bladder overactivity. In clinical practice, the oral extended-release tablet formulation is most widely prescribed due to its ability to provide stable drug levels and sustained symptom control. Physicians frequently use mirabegron either as a standalone therapy or in combination with antimuscarinic agents to enhance therapeutic outcomes. The medication works by improving bladder compliance and reducing involuntary bladder contractions that contribute to leakage episodes. One of the major advantages of mirabegron in this application is its reduced risk of dry mouth and cognitive complications compared with older anticholinergic drugs. This has supported broader adoption in long-term incontinence management programs, particularly among aging populations seeking effective symptom control with improved tolerability and treatment adherence.
Prostate Disorders Management : Another emerging application of Mirabegron is in the supportive management of urinary symptoms associated with Benign Prostatic Hyperplasia and related prostate disorders. In this context, mirabegron is typically administered as an oral extended-release tablet alongside alpha-blockers or other prostate therapies. The drug helps address persistent storage symptoms such as urinary urgency and increased frequency that often remain after primary prostate treatments. By relaxing bladder smooth muscle and improving functional bladder capacity, mirabegron supports better urinary control without interfering with prostate-targeted medications. This complementary mechanism provides a clinical advantage for patients experiencing mixed lower urinary tract symptoms. Increasing awareness among urologists regarding combination therapy strategies has expanded the role of mirabegron in prostate disorder management, particularly for men who continue to experience bothersome bladder symptoms despite standard prostate treatments.

Recent Developments

Recent developments in the Mirabegron market reflect a strategic shift toward broader generic availability and patient-centric treatment models in the overactive bladder therapeutics ecosystem. Patent settlements between Astellas Pharma and generic manufacturers such as Lupin Limited and Zydus Lifesciences are enabling continued commercialization of generic mirabegron in the U.S., stabilizing supply while intensifying price competition in urology drug markets. A key market trend is the increasing adoption of β3-adrenoceptor agonists for overactive bladder management, supported by better patient adherence and reduced anticholinergic side-effect burden. This shift is expanding prescribing patterns across aging populations and strengthening demand for once-daily oral bladder control medications.

December 2024 : Pharmacia Corporation has released an iteration of mirabegron named Mirabegron Advanced on a global scale to better serve the market for overactive bladder syndrome.
October 2024 : Janssen Pharmaceuticals has revealed that they are conducting a trial, for a medication blend involving the use of mirabegron and Fesoterodine to better address urinary incontinence issues.
July 2024 : Novartis has been given the light, for its widely distributed generic form of mirabegron to boost competition in the market.

Impact of Industry Transitions on the Mirabegron Market

As a core segment of the Pharmaceutical industry, the Mirabegron market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Anticholinergic Therapies to Beta-3 Agonist Treatment Approaches and Growing Integration of Combination Therapy Strategies in Urology and Prostate Care have redefined priorities across the Pharmaceutical sector, influencing how the Mirabegron market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Anticholinergic Therapies to Beta-3 Agonist Treatment Approaches

The bladder disorder treatment landscape is undergoing a gradual transition from traditional anticholinergic drugs to beta-3 adrenergic receptor agonist therapies such as Mirabegron. Healthcare providers increasingly prefer medications that provide effective symptom relief while minimizing cognitive or systemic side effects, particularly for elderly patients with Overactive Bladder. This shift is influencing pharmaceutical research priorities and encouraging drug manufacturers to invest in alternative bladder treatment mechanisms. The transition is also impacting the urology therapeutics industry by driving demand for safer long-term medications and reshaping treatment guidelines. Additionally, healthcare providers and hospital pharmacies are expanding formularies to include newer bladder disorder therapies that improve patient adherence and overall treatment outcomes.
02

Growing Integration of Combination Therapy Strategies in Urology and Prostate Care

Another notable industry transition involves the increasing integration of Mirabegron within combination therapy strategies for managing complex urinary conditions. Urologists are combining mirabegron with antimuscarinic agents or medications used in Benign Prostatic Hyperplasia management to address persistent bladder storage symptoms. This trend is influencing both the urology pharmaceutical market and the broader prostate care industry by encouraging cross-therapeutic treatment approaches. Pharmaceutical companies are exploring combination drug formulations and co-prescription strategies to improve treatment outcomes for patients experiencing mixed urinary symptoms. The transition toward integrated therapy models is expected to strengthen collaboration between urology specialists, pharmaceutical manufacturers, and healthcare providers while expanding treatment options for patients with multifactorial urinary disorders.